Merk Germany to buy Silence Britain
German company Merck intends to acquire British company Silence Therapeutics for $1.1 billion, aimed at expanding its capabilities in treating rare diseases. The deal, valued at $20 per American Depositary Share (ADS), represents an 82% premium over the stock's average price over the past 30 days and is expected to be completed in the first quarter of 2027 through funding from new loans. Through this acquisition, Merck seeks to strengthen its ability to develop targeted treatments for rare conditions, especially as Silence approaches the final stage of clinical trials for its drug "DIFSIRAN," which aims to treat polycythemia vera—a rare blood disorder associated with cancer that causes excessive production of red blood cells and raises the risk of mortality. The deal underscores Merck's strategic expansion through extensive acquisitions to enhance its presence in the specialized pharmaceuticals and life sciences sectors.
Notice: This Is an AI-Generated Summary
Comments (0)